Cocrystal Pharma, Inc. (COCP) Stock Forecast
COCP analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 2 analysts
- Price target
- $8.00 average of analyst targets
- Upside to target
- +684.3% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.17
- 52-week range
- $0.82 – $1.57
COCP analyst ratings
2 analystsNumber of analysts at each rating.
COCP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
COCP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.17 | −$0.22 | −$0.14 | −$0.19 | +8.8% | 3 |
| Current fiscal year (2026) | −$0.72 | −$0.76 | −$0.69 | −$0.78 | +7.0% | 2 |
| Next fiscal year (2027) | −$0.47 | −$0.58 | −$0.37 | −$0.72 | +34.5% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
COCP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 3 |
| Current fiscal year (2026) | $110.0M | $0 | $330.0M | 0.0% | 3 |
| Next fiscal year (2027) | $0 | $0 | $0 | −100.0% | 2 |
COCP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
COCP revenue: reported and forecast
COCP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.17 | −$0.17 | −$0.14 | −$0.14 | −$0.17 | −1.0% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.69 | −$0.69 | −$0.69 | −$0.69 | −$0.72 | +5.8% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.64 | −$0.64 | −$0.58 | −$0.58 | −$0.47 | −25.8% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
COCP earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; COCP beat in 9 of 12.
What analysts expect from COCP
2 analysts cover Cocrystal Pharma; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.00, 684.3% above the latest close of $1.02. Analysts expect earnings of −$0.72 per share for 2026, +7.0% from a year earlier. For 2027 the average estimate is −$0.47 per share. Cocrystal Pharma beat the EPS estimate in 9 of the last 12 quarters.
Related: COCP income statement, COCP key metrics, COCP chart. See the COCP stock overview for the latest quote and news.
COCP forecast FAQ
What is Cocrystal Pharma's price target?
The average analyst price target for Cocrystal Pharma is $8.00, 684.3% above the latest close of $1.02.
Is Cocrystal Pharma a buy, hold or sell?
Of 2 analysts covering Cocrystal Pharma, 2 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Cocrystal Pharma's EPS forecast?
Analysts forecast −$0.72 per share for 2026 (range −$0.76 to −$0.69); for 2027 the estimate is −$0.47.
What is Cocrystal Pharma's revenue forecast?
The average revenue estimate for 2026 is $110.0 million, growth of 0.0%.
When does Cocrystal Pharma report earnings?
Cocrystal Pharma is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.17.
Does Cocrystal Pharma usually beat earnings estimates?
Cocrystal Pharma reported EPS at or above the analyst estimate in 9 of the last 12 quarters.